Therapeuticsmd Inc Stock Price, News & Analysis

TherapeuticsMD, Inc. (TXMD) announced a strategic licensing agreement with Mayne Pharma for U.S. commercialization of its products. TXMD will receive approximately $153.1 million, including $140.0 million upfront and $13.1 million for working capital. This transaction allows TXMD to repay debt and transition into a pharmaceutical royalty company. The agreement includes potential royalty and milestone payments totaling $42.6 million. The closing is expected by the end of 2022, pending regulatory approvals.

TherapeuticsMD (TXMD) reported Q3 2022 revenues of $20.9 million, a $4.5 million decline year-over-year, despite a 10% growth in ANNOVERA prescriptions. Operating expenses decreased by $22 million to $37.9 million. The net loss for the quarter was $29 million ($3.13 per share), improved from a $47.4 million loss in Q3 2021. The company completed a $7 million investment from Rubric Capital, enhancing liquidity amid ongoing strategic assessments.

TherapeuticsMD, Inc. (NASDAQ: TXMD) announced a $7 million investment in Series A Preferred Stock from Rubric Capital Management LP. The funds will be used for working capital and extend the maturity date of a financing agreement with Sixth Street Specialty Lending, Inc. to November 30, 2022. The Board is exploring strategic alternatives to improve the financial position of the company.

TherapeuticsMD (NASDAQ: TXMD) has secured a $7 million private investment in its Series A Preferred Stock from Rubric Capital Management. The funds are intended for working capital. The investment extends the maturity date of its financing agreement with Sixth Street Specialty Lending to October 31, 2022, with a potential further extension to November 30, 2022 if additional $7 million in equity capital is raised. The Company’s management continues to explore strategic alternatives to enhance its long-term financial position.

TherapeuticsMD, Inc. (NASDAQ: TXMD) has appointed Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-CEOs, succeeding Mr. Hugh O’Dowd. Dr. Bernick, a co-founder and previous Chief Scientific and Medical Officer, is expected to lead the company through a strategic alternatives process. Mr. Glickman, the former Chief Business Officer, brings 30 years of experience. Additionally, Tommy Thompson has transitioned to Executive Chairman from Chairman of the Board. The leadership change aims to enhance efforts to evaluate strategic options and deliver shareholder value.

TherapeuticsMD (TXMD) reported a solid Q2 2022 with total net revenue reaching $28.6 million, a 24% increase year-over-year. ANNOVERA revenue surged to $18.3 million, marking a 28% increase in prescriptions. Operating expenses dropped 21%, and the company achieved net income of $112.3 million, driven by a $143.4 million gain from divesting its vitaCare unit. Cash on hand decreased to $26.3 million by June 30, 2022, while $90.8 million remains under the financing agreement.

TherapeuticsMD, Inc. (NASDAQ: TXMD) will report its Q2 2022 financial results on August 15, 2022, at 8:30 a.m. ET. Executive management will host a conference call to discuss these results, accessible via audio conference line and a webcast. The live stream and a replay will be available on the TherapeuticsMD website for 30 days. The company focuses on developing healthcare products for women, addressing health issues related to family planning, reproductive health, and menopause management.

TherapeuticsMD (NASDAQ: TXMD) has secured a $15 million private investment from Rubric Capital Management to support its operating capital needs. This financing comes alongside an extension of its debt maturity date with Sixth Street Partners to September 30, 2022, with options for further extensions if additional equity of $7 million is raised.

The investment is anticipated to enable the company to continue meeting demand for its women's healthcare products while evaluating strategic options to enhance shareholder value.

TherapeuticsMD, Inc. (NASDAQ: TXMD) has announced the anticipated termination of its Merger Agreement with EW Healthcare Partners due to the failure to acquire the required majority of shares by the tender offer deadline on July 12, 2022. Consequently, the tender offer has expired, and the Company expects the agreement to terminate following July 13, 2022. Despite this setback, TherapeuticsMD plans to maintain normal operations.